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Abstract Multiple malignancies may occur in the same
patient, and a few reports describe cases with multiple
hematologic and non-hematologic neoplasms. We report the
case of a patient who showed the sequential occurrence of
four different lymphoid neoplasms together with a squa-
mous cell carcinoma of the lung. A 62-year-old man with
adenopathy was admitted to the hospital, and lymph node
biopsy was positive for low-grade follicular lymphoma. He
achieved a partial remission with chemotherapy. Two years
later, a PET-CT scan showed a left hilar mass in the lung;
biopsy showed a squamous cell carcinoma. Simultaneously,
he was diagnosed with diffuse large B cell lymphoma in a
neck lymph node; after chemo- and radiotherapy, he
achieved a complete response. A restaging PET-CT scan
2 years later revealed a retroperitoneal nodule, and biopsy
again showed a low-grade follicular lymphoma, while a
biopsy of a cutaneous scalp lesion showed a CD30-positive
peripheral T cell lymphoma. After some months, a liver
biopsy and a right cervical lymph node biopsy showed a
CD30-positive peripheral T cell lymphoma consistent with
anaplastic lymphoma kinase-negative anaplastic large cell
lymphoma. Flow cytometry and cytogenetic and molecular
genetic analysis performed at diagnosis and during the
patient’s follow-up confirmed the presence of two clonally
distinct B cell lymphomas, while the two T cell neoplasms
were confirmed to be clonally related. We discuss the
relationship between multiple neoplasms occurring in the
same patient and the various possible risk factors involved
in their development.
Keywords DiffuselargeBcelllymphoma.Follicular
lymphoma.Anaplasticlargecelllymphoma.Riskfactors.
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Introduction
The appearance of multiple malignancies in the same
patient is a rare occurrence, which can either be synchro-
nous or metachronous. The incidence of multiple malig-
nancies varies with age, sex, geographic origin, and site and
type of tumors. The etiology is multifactorial, and some of
the factors involved in the pathogenesis of these conditions
include genetic predisposition, immunodeficiency, radiation
therapy, chemotherapy, and various infectious agents,
including Epstein–Barr virus (EBV) [1]. There are several
reports of patients with a hematologic malignancy who
develop a non-hematologic cancer [2–5], but only few case
reports describe patients with multiple hematologic and
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unusual case of a patient who developed low-grade
follicular lymphoma, squamous cell carcinoma of the lung,
diffuse large B cell lymphoma (DLBCL) with a clonality
distinct from the follicular lymphoma, peripheral T cell
lymphoma of the skin, and systemic peripheral T cell
lymphoma consistent with anaplastic lymphoma kinase
(ALK)-negative anaplastic large cell lymphoma (ALCL)
that was clonally related to the cutaneous lymphoma. We
discuss the possibility of a relationship between these
different neoplasms developing in the same patient and the
importance of understanding various risk factors involved
in the development of multiple malignancies.
Case history
In 2003, a 62-year-old former smoker with known asbestos
exposure was admitted to the hospital for chest pain and
cough. He reported a family history of malignancies, in that
his father died of lip cancer, a maternal uncle from
lymphoma and lung cancer, and a second cousin from lung
cancer. Chest X-ray demonstrated adenopathy, and a para-
tracheal lymph node biopsy showed grade 1 of 3 follicular
lymphoma (Table 1). Conventional cytogenetics performed
on the lymph node revealed a complex karyotype, with a t
(14;18); flow cytometry revealed a lambda light-chain-
restricted B cell population (Table 2, Fig. 1a). Staging PET
scan showed lymphoma involving the left chest, neck, and
spleen. He was treated with three cycles of fludarabine,
Cytoxan and Rituxan (FCR). The patient had a partial
remission and was followed up every 4 months. In late
2005, he presented to his oncologist after an episode of
hemoptysis. A chest X-ray showed a left hilar lesion. A
subsequent PET-CT scan showed a left hilar mass, a 9-cm
mass in the spleen, and additional PET avid lymph nodes in
the left neck, paraesophageal region, and abdomen. The
patient then had a bronchoscopy and transbronchial biopsy;
the biopsy showed a poorly differentiated squamous cell
carcinoma (Table 1). In early 2006, a left neck lymph node
was excised on which a diagnosis of DLBCL was rendered
(Table 1, Fig. 2a–c). Cytogenetic analysis of the lymph
node revealed a BCL6 gene rearrangement (confirmed by
metaphase fluorescence in situ hybridization [FISH]) and a
complex karyotype distinct from the prior findings of 2003,
and flow cytometric analysis revealed a kappa light-chain-
restricted B cell population (Table 2, Fig. 1b). Immuno-
globulin heavy chain (IgH) gene rearrangement studies by
polymerase chain reaction (PCR) showed the presence of a
clonal B cell population (Table 2, Fig. 4b–d). Since the
patient was not a surgical candidate for the non-small cell
lung cancer, two cycles of cisplatin and etoposide (VP-16)
were administered. In order to maximize the therapeutic
effect on the DLBCL, rituximab was added to the regimen.
Following this initial induction chemotherapy, eight cycles
of rituximab, ifosfamide, carboplatin, and etoposide and
Table 1 Histological and immunohistochemical findings of hematologic and non-hematologic malignancies
Month/year Sample Morphology Immunohistochemistry and in situ
hybridization
Diagnosis
11/2003 Paratracheal
lymph node
Nodular proliferation of predominantly
small to intermediate sized lymphoid
cells with irregular to cleaved nuclei
CD20+, CD10+, bcl-6+, bcl-2+
(subset, weak)
Follicular lymphoma,
grade 1 of 3
12/2005 Bronchoscopic
biopsy
Not applicable Not performed Squamous cell carcinoma
poorly differentiated
01/2006 Left neck
lymph node
Diffuse infiltrate of large atypical
lymphoid cells with oval, irregular,
and multilobated nuclei and scant
cytoplasm (Fig. 2a–c)
Pax5+, bcl-2+, bcl-6−/+, cyclin D1−,
90% Ki67+, EBER−
Diffuse large B cell
lymphoma
02/2008 Skin biopsy,
right scalp
Dense dermal and subcutaneous
infiltrate of large atypical lymphoid
cells with irregular nuclei (Fig. 4d–f)
CD3+, CD30+, ALK1− CD30-positive peripheral
T cell lymphoma
03/2008 Retroperitoneal
lymph node
Diffuse and vaguely nodular infiltrate
of small atypical centrocytes
(Fig. 2d–f)
Pax5+, bcl-6+, CD10+, bcl-2−,
5–10% Ki-67+, CD21+ follicular
dendritic cell meshworks
Follicular lymphoma,
grade 1 of 3
10/2008 Right cervical
lymph node
and liver
Diffuse proliferation of large atypical
lymphoid cells with round, oval, or
occasionally indented nuclei and
frequent mitoses (Fig. 4a–c)
CD3+, CD2+, CD30+ (strong and
diffuse), ALK1−, MUM1+ and
bcl-2+; CD5−, CD4−, CD8−,
granzyme B−, perforin−, CD20−,
CD79a−, CD10−, bcl-6−, CD56−,
>90% Ki-67+, EBER−
Anaplastic large cell
lymphoma, ALK
negative, T-lineage
EBER Epstein–Barr virus RNA, ALK anaplastic lymphoma kinase
164 J Hematopathol (2009) 2:163–170radiotherapy were administered. The treatment course was
complicated by expected myelosuppression, but he
achieved a complete response. In March 2008, a restaging
total body PET-CT scan revealed new left retroperitoneal
nodules and enlarging right internal iliac chain lymph nodes
suspicious for lymphoma recurrence. A retroperitoneal
nodule was biopsied and found to contain an atypical
lymphoid proliferation consistent with grade 1 of 3
follicular lymphoma (Table 1, Fig. 2d–f). Interestingly,
flow cytometric analysis of this lymphoma revealed a
clonal lambda light chain population, similar to that seen in
2003, while the analysis of 2006 performed on the DLBCL
revealed a clonal kappa light chain population (Table 2).
IgH gene rearrangement studies of the 2008 follicular
lymphoma showed a clonal rearrangement with a different-
sized PCR product from the 2006 DLBCL (Table 2,
Fig. 4a–d). Finally, FISH analysis of paraffin-embedded
tissue from the 2008 follicular lymphoma demonstrated the
presence of a BCL2 gene rearrangement and absence of a
BCL6 gene rearrangement (Table 2). The patient was
treated with four doses of rituximab administered weekly.
Just prior to his follicular lymphoma recurrence, in
February 2008, the patient developed a scalp lesion that
was biopsied and showed a diffuse CD30-positive, ALK-
negative cutaneous T cell infiltrate (Table 1, Fig. 3d–f). The
lesion spontaneously resolved without further treatment,
and a primary cutaneous CD30-positive T cell lymphopro-
liferative disorder was the presumed diagnosis. However, in
October 2008, a restaging total body CT scan revealed
progressive adenopathy and enlarging liver and spleen
lesions. Biopsies of the liver and right cervical lymph node
showed a peripheral T cell lymphoma consistent with ALK-
negative ALCL (Table 1, Fig. 3a–c). T cell receptor (TCR)
gene rearrangement studies of the right cervical lymph node
and scalp biopsies showed clonal T cell populations with
PCR products of similar size, confirming that the two T cell
lymphomas were clonally related and supporting a diag-
nosis of systemic ALK-negative ALCL with initial mani-
festation in the skin (Table 2). The patient was treated with
six cycles of dose-reduced cyclophosphamide, doxorubicin,
vincristine, and prednisone and recently underwent non-
myeloablative allogeneic stem cell transplant from a
matched-related donor.
Discussion
Various factors may be involved in the pathogenesis of
multiple malignancies such as age, gender, genetic predis-
position, chemotherapy and/or radiation therapy, immuno-
deficiency, EBV infection [1], and environmental risk
factors like smoking or asbestos exposure. We report the
case of a patient in whom some of these factors may have
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J Hematopathol (2009) 2:163–170 165been involved in the pathogenesis of his multiple malig-
nancies. In 2003, the patient was diagnosed with lambda-
positive, low-grade follicular lymphoma (Table 1) treated
with three courses of FCR, resulting in a partial remission.
Two years later, squamous cell carcinoma of the lung,
together with DLBCL, was diagnosed (Table 1, Fig. 2a–c).
The cytogenetic and flow cytometric analyses in 2003
revealed different results from those performed in 2006
(Table 2, Fig. 1a–b), supporting that the two B cell
lymphomas were clonally unrelated. In 2008, a retroperito-
neal lymph node biopsy again showed the presence of low-
grade follicular lymphoma (Table 1,F i g .2d–f). Flow
cytometry revealed this to be lambda positive, and FISH
analysis showed a BCL2 gene rearrangement, similar to the
2003 follicular lymphoma, while the DLBCL in 2006 was
kappa positive with a BCL6 gene rearrangement, further
substantiating two clonally distinct B cell neoplasms
(Table 2, Fig. 1a–b). Finally, molecular genetic analysis
confirmed that the DLBCL and the follicular lymphoma
had separate clonal origins (Table 2, Fig. 4a–d). Interest-
ingly, the patient also developed a cutaneous CD30-
positive, ALK-negative peripheral T cell lymphoma that
was thought to represent a primary cutaneous CD30-
positive lymphoproliferative disorder (Table 1, Fig. 3d–f).
However, after 8 months, biopsies of the liver and right
cervical lymph node showed a peripheral T cell lymphoma
consistent with ALCL, ALK negative (Table 1, Fig. 3a–c).
The skin and systemic T cell lymphomas shared the same
clonal TCR gene rearrangements by PCR, suggesting that
both neoplasms arose from the same cell of origin (Table 2).
In summary, this patient had two different B cell lympho-
mas, a systemic ALK-negative ALCL initially manifesting
as a localized skin lesion, and squamous cell carcinoma of
the lung.
Fig. 1 Cytogenetic analysis of
the patient's B cell lymphomas.
Cytogenetic analysis of the 2003
lymph node showing grade 1
follicular lymphoma (a)
revealed a complex karyotype
(arrows), with a translocation
between chromosomes 14 and
18 indicating a rearrangement
involving IGH and BCL2.
Analysis of the 2006 lymph
node with DLBCL also showed
a complex karyotype (arrows),
which was distinct from that of
the prior follicular lymphoma
(b). In particular, t(14;18) was
absent. Metaphase FISH analy-
sis revealed a BCL6 rearrange-
ment involving chromosome 3
(not shown). For complete
karyotypes, see Table 2
166 J Hematopathol (2009) 2:163–170A relationship between this patient’s different malignan-
cies may be hypothesized based upon genetic predisposi-
tion, environmental risk factors, gender, age, and therapy
administered for his initial low-grade follicular lymphoma.
Lung cancer is reported to be the second most frequently
diagnosed secondary malignancy following treatment for
indolent non-Hodgkin’s lymphoma, after myelodysplastic
syndrome or acute myeloid leukemia [8]. Factors with a
statistically significant negative impact on time free from a
second tumor include age 45–64 years at initial treatment,
male gender and fludarabine-containing therapy. The
patient we describe is a 62-year-old male former smoker
with known asbestos exposure who was treated with
fludarabine and who had a family history of malignancies
that included lung cancer. In addition, prior therapy with
fludarabine may have contributed to an immunodeficient
state that allowed the growth of a previously undetected
cancer [9]. Therefore, it is likely that multiple factors
contributed to the development of his lung cancer.
The development of this patient's subsequent DLBCL
and ALK-negative ALCL is more difficult to explain, but
immunologic factors may have played a role. The squa-
mous cell carcinoma, diagnosed in 2006, may have
preceded this patient’s hematologic malignancies and
remained occult, resulting in an immunological imbalance
that later contributed to the development of lymphoma.
Therapy with fludarabine and age-related immunosenes-
cence may lead to the development of EBV-positive B cell
lymphomas [10, 11]. However, this patient's DLBCL was
EBV negative by in situ hybridization for EBV RNA
(Table 1), implying that the lymphoma was unrelated to
treatment with fludarabine or age. Systemic ALK-negative
Fig. 2 Histologic and immunohistochemical findings of the patient's
B cell lymphomas. Biopsy of enlarged left neck lymph node from
2006 revealed an infiltrate of large atypical lymphoid cells with oval,
irregular, and multilobated nuclei and prominent nucleoli (a). The
cells effaced the nodal architecture in a diffuse pattern (b) and were
positive for Pax5 (c), consistent with DLBCL. In 2008, a retroperi-
toneal lymph node core biopsy showed a proliferation of small
lymphocytes with irregular nuclei, consistent with centrocytes (d),
forming vague follicle structures (e) and staining positively for Pax5
(f). The findings were consistent with relapsed follicular lymphoma,
grade 1 of 3
J Hematopathol (2009) 2:163–170 167ALCL is not known to be associated with specific risk
factors [12]. It is likely that the etiology underlying the
development of multiple malignancies in this patient was
multifactorial in nature and that both non-immunologic and
immunologic factors (acting through a mechanism other
than EBV) were involved.
This case illustrates the importance of obtaining an
accurate history at the time of a patient’s initial diagnosis
and of performing appropriate immunophenotypic, cytoge-
netic, and molecular genetic analyses during the course of a
patient's diagnostic work-up. These actions help to identify
important risk factors and prognostic indicators that assist
in determining the most appropriate treatment strategies,
taking into account possible side effects and the potential
development of secondary neoplasia. Close long-term
follow-up of hematologic malignancies is important not
only for monitoring response to therapy but also for
comparing subsequent neoplasms that may develop after
the initial diagnosis to the initial pathology. The case of our
patient emphasizes that new lesions developing in an
individual with an established diagnosis of malignancy
cannot be assumed to represent relapse of the original
neoplasm. Finally, cytogenetic and molecular genetic
analyses of tumors from patients with multiple malignan-
cies may help to improve our understanding of the possible
relationship between multiple primary malignancies and
may help to predict the risk of a second tumor before its
manifestation.
Fig. 3 Histologic and immunohistochemical findings of the patient’s
T cell lymphomas. In 2008, biopsy of an enlarged right neck lymph
node showed a diffuse proliferation of large atypical lymphoid cells
with round to irregular nuclei, sometimes reniform nuclei; mitotic
figures were readily apparent (a). The tumor cells were positive for
CD3 (b), strongly positive for CD30 (c), and negative for ALK-1 (not
shown). A diagnosis of ALCL, ALK negative was made. Eight
months earlier, biopsy of the patient’s 2008 scalp lesion revealed a
dense dermal infiltrate of large atypical lymphoid cells with irregular
nuclei (d). The infiltrate extended to involve subcutaneous tissue and
was positive for CD3 (e) and CD30 (f) and negative for ALK-1 (not
shown). Subsequent TCR gene rearrangement studies supported that
the prior skin biopsy represented secondary cutaneous involvement by
a systemic ALK-negative ALCL
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